Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial

What Was Tested

This clinical study looks at Semaglutide.

Treatment adherence by people with type 2 diabetes (T2D) is overall suboptimal, which can hinder glycemic control.

Multiple adherence barriers have been identified, such as the dislike and fear of injections.

Who Took Part

The abstract describes 20 participants taking part.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

Potential participants are recruited through announcements on social media and digital mail sent to their official digital mailbox (e-boks).

Glycemic control will be assessed using an unblinded continuous glucose monitoring sensor that the participants will wear.

How the Study Was Run

In design terms this was an open-label study.

Nothing was hidden in this open-label Semaglutide study: the participants and staff both knew the treatment.

This prospective, noninterventional, open-label, clinical trial with a duration of 12 weeks will be conducted in Denmark.

Participants are asked to report any cases of nausea or vomiting in terms of time of occurrence, duration, and severity.

The primary endpoint is change from baseline to end-of-study time-in-range derived from continuous glucose monitoring data.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Metformin, Hypoglycemic Agents, Glycemic Control, Blood Glucose and Denmark.

Author keywords: continuous glucose monitoring, medication adherence, observational study, oral antidiabetic drug and oral semaglutide.

What This Means in Plain Language

The paper is an open-label study of Semaglutide in 20 participants.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (JMIR research protocols), a journal based in Canada.

More context: the Semaglutide compound page, all human trials.